Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Stevanato Group S.p.A.NYSE: STVN

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA growth accelerates

Q2 FY2026 EBITDA of €64.29M rose 3.1% year over year, ahead of the -4.5% change in trailing-twelve-month EBITDA. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.

Context

  • EBITDA amounted to 25.6% of revenue in FY2025, up 3.2 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 10 analysts of €343.46M (+17.6%) for the fiscal year ending Dec 2026, a pace similar to FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€64.29M-1.2% QoQ
Last fiscal yearDec 2025
€292.01M+17.8% YoY
LTMJun 2026
€296.36M-4.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.1%+16.8%+13.8 pp
1 year+17.8%+17.6%-0.2 pp
3-year CAGR+4.4%+17.0%+12.6 pp
5-year CAGR+20.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
292.01M EUR
Year-over-year change
+17.8%
4-year CAGR
+6.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.5% is the 7th highest of 11, against a peer median of +5.3%.
  • EBITDA amounts to 24.3% of revenue for STVN, versus a peer median of 16.6%.
STVN Competitors
EBITDA for STVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATRAptarGroup, Inc.LTM Jun 2026$822.22M USD+1.7%+10.9%20.9%
BLCOBausch + Lomb CorporationLTM Jun 2026$742M USD+61.3%-3.6%13.9%
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$709.15M USD+59.1%+5.5%4.6%
CHEChemed CorporationLTM Jun 2026$431.72M USD-4.8%+2.4%16.6%
MASIMasimo CorporationLTM Apr 2026$344.5M USD+414.9%-1.0%22.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$341.34M USD+9.0%+22.4%21.2%
STVNStevanato Group S.p.A.LTM Jun 2026€296.36M EUR-4.5%+4.4%24.3%
AVTRAvantor, Inc.LTM Jun 2026$125.3M USD-91.1%-55.0%1.9%
TFXTeleflex IncorporatedLTM Jun 2026-$158.49M USD-126.4%-25.5%6.1%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-$176.13M USD+22.9%—22.7%
NUVLNuvalent, Inc.LTM Mar 2026-$334.38M USD-11.3%——
Peer median (excluding STVN) —+5.3%+0.7%16.6%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue843.92M983.68M1.09B1.1B1.14B
Cost of Revenue578.52M663.88M745.46M801.72M809.15M
Gross Profit265.41M319.8M339.89M302.32M330.33M
Gross Margin31.4%32.5%31.3%27.4%29.0%
Research & Development29.62M34.39M35.67M31.67M24.4M
Selling, General & Admin82.95M111.83M113.92M118.6M122.85M
Operating Expenses103.18M127.37M139.17M141.18M147.25M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
EBITDA226.93M256.4M272.35M247.8M292.01M
EBITDA Margin26.9%26.1%25.1%22.4%25.6%
Operating Income162.23M192.43M200.72M161.14M183.08M
Operating Margin19.2%19.6%18.5%14.6%16.1%
Interest Income548K648K792K1.72M12.49M
Interest Expense4.87M3.94M4.32M6.86M21.8M
Other Income / Expenses3.45M(4.79M)(11.17M)(854K)(1.44M)
Income Before Tax165.67M187.64M189.55M160.29M181.64M
Pre-Tax Margin19.6%19.1%17.5%14.5%15.9%
Income Tax Expense31.4M44.63M43.86M42.52M47.35M
Net Income134.32M142.85M145.63M117.78M134.28M
Net Margin15.9%14.5%13.4%10.7%11.8%
EPS (Basic)0.530.530.550.430.49
EPS (Diluted)0.530.530.550.430.49
Weighted Avg Shares264.7M264.7M264.95M272.87M273M
Weighted Avg Shares (Diluted)264.7M264.7M264.98M272.88M273M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.